The Portuguese government has finally reached an agreement with an American pharmaceutical firm to bring an innovative drug to treat Hepatitis C to Portugal.
The deal comes one year after the drug from Gilead Sciences reached Europe.
According to reports the Ministry of Health and national drugs watchdog Infarmed managed to negotiated a price that will enable more patients to be treated for less than €25,000 per treatment.
Newspaper Público reports that the plan is to treat between 10,000 and 12,000 patients with the new drug over the next three years.
Labels: drug coverage, Gilead, Portugal